Latest Briefings

Protecting reputation in the spotlight of an investigation

Global business is increasingly familiar with the prospect of short-notice public investigatory attention, whether from regulators, law enforcement, political forces or as a consequence of sanctions, and this can – in in some cases – devastate individual and corporate reputation.

Protecting reputation in the spotlight of an investigation

Despite the fact that the threat of an investigation alone can be enough to paralyse a business, early warning signs are often missed and businesses can mistake an investigation risk for a reputation risk. Those who handle serious issues well are able to triage the issue at an early stage and identify its potential impact, […]

Bill 64 marks a new direction in Quebec privacy law — Key takeaways for businesses

On September 22, 2021, the Quebec government adopted Bill 64, An Act to modernize legislative provisions as regards the protection of personal information, enacting significant changes to the requirements governing the use and protection of personal information under various statutes, including notably the Act respecting the protection of personal information in the private sector and the Act respecting Access to documents held by public bodies and the Protection of personal information.



Macfarlanes leads as Novartis moves HQ to London

Macfarlanes is advising on Novartis’s HQ move to White City, as the Swiss drugs giant sets its sights on joining a cluster of life sciences companies in West London. Novartis’s 600 HQ staff will relocate from Frimley in Surrey to the WestWorks building on the White City Place campus within the UK’s “golden triangle” bioscience hub […]


Hogan Lovells wins the top role for Novartis in $9bn pharma deal

Hogan Lovells and Cravath Swaine & Moore have won the top roles on Novartis’ $9bn purchase of Chicago-based gene therapy company AveXis. The deal, in which the Swiss pharmaceutical giant is offering $218 per share for AveXis, is being led by Hogan Lovells Washington DC-based corporate transactions partner Joseph Gilligan who is advising Novartis. He is working alongside New […]


A&O, Osborne Clarke and Proskauer Rose advise on $1.7bn Novartis deal

Allen & Overy (A&O), Osborne Clarke (OC) and Proskauer Rose have taken mandates advising on the $1.7bn (£1bn) sale of Swiss pharmaceutical giant Novartis’ transfusion diagnostics unit to Spanish plasma therapies company Grifols. Barcelona-headquartered Grifols will acquire the transfusion diagnostics unit of Novartis for US$1,675bn (£1,04bn). The assets include medical products and technology, as well […]


Novartis unveils panel designed to build ‘long-term partnerships’

Novartis has announced the results of its first panel review since the company’s $40bn takeover of Alcon, with three magic circle firms – Allen & Overy, Freshfields Bruckhaus Deringer and Linklaters – securing spots on the global roster along with two US firms. Pharma company Novartis’s new panel, called the legal preferred firm programme, is […]

Find legal roles

Make your next move with The Lawyer Careers. Search and apply for thousands of vacancies, or receive email alerts for new roles when they go live. Whether you're looking at private practice, in-house legal or an exciting business support role, you'll find your future here.

Search vacancies